BRPI0515777A - biossìntese isenta de células de ácido nucléico de alta qualidade e usos dos mesmos - Google Patents

biossìntese isenta de células de ácido nucléico de alta qualidade e usos dos mesmos

Info

Publication number
BRPI0515777A
BRPI0515777A BRPI0515777-3A BRPI0515777A BRPI0515777A BR PI0515777 A BRPI0515777 A BR PI0515777A BR PI0515777 A BRPI0515777 A BR PI0515777A BR PI0515777 A BRPI0515777 A BR PI0515777A
Authority
BR
Brazil
Prior art keywords
nucleic acid
free
biosynthesis
amplification
therapeutic
Prior art date
Application number
BRPI0515777-3A
Other languages
English (en)
Inventor
Yin Chen
Frederic Kendirgi
Frank Vazquez
Malcolm Skolnick
Original Assignee
Cytogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogenix Inc filed Critical Cytogenix Inc
Publication of BRPI0515777A publication Critical patent/BRPI0515777A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/10—Nucleotidyl transfering
    • C12Q2521/101—DNA polymerase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"BIOSSìNTESE ISENTA DE CéLULAS DE áCIDOS NUCLéICO DE ALTA QUALIDADE E USOS DOS MESMOS". A invenção proporciona um método aperfeiçoado de amplificação isento de células capaz de produzir grandes quantidades de ácidos nucléicos de qualidade terapêutica e métodos de uso do ácido nucléico sintetizado em pesquisa, produtos terapêuticos e outras aplicações. Os métodos combinam vários diferentes procedimentos do estado da técnica e coordenam suas aplicações a ácidos nucléicos sintéticos de preço acessível para fins terapêuticos. Ele combina amplificação por rolamento de círculo in vitro, polimerases de alta fidelidade, primers de alta afinidade e modelo eficaz especificamente projetado para aplicações em particular. Para fins de expressão, os modelos contêm um cassete de expressão incluem um promotor eucariota, a seqüência de codificação para o gene de interesse e uma seqüência de térmico eucariota. Após amplificação, concatâmeros são subseqüentemente processados de acordo com seu uso pretendido e podem incluir: digestão com enzima de restrição para a produção de cassetes de expressão curtos (SECs); etapas de ligação para circularizar o SEC (CNAs); e/ou etapas de superenrolamento para produzir sCNAs. O produto final contém níveis quase não detectáveis de endotoxina bacteriana.
BRPI0515777-3A 2004-12-11 2005-12-12 biossìntese isenta de células de ácido nucléico de alta qualidade e usos dos mesmos BRPI0515777A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63541804P 2004-12-11 2004-12-11
US68071605P 2005-05-13 2005-05-13
US70534805P 2005-08-04 2005-08-04
PCT/US2005/045028 WO2006063355A2 (en) 2004-12-11 2005-12-12 Cell free biosynthesis of high-quality nucleic acid and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0515777A true BRPI0515777A (pt) 2008-08-05

Family

ID=36337344

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515777-3A BRPI0515777A (pt) 2004-12-11 2005-12-12 biossìntese isenta de células de ácido nucléico de alta qualidade e usos dos mesmos

Country Status (9)

Country Link
US (1) US20080305142A1 (pt)
EP (1) EP1819828A2 (pt)
JP (1) JP2008522628A (pt)
KR (1) KR20070093992A (pt)
AU (1) AU2005314431B2 (pt)
BR (1) BRPI0515777A (pt)
CA (1) CA2590933A1 (pt)
IL (1) IL183778A0 (pt)
WO (1) WO2006063355A2 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007018744A2 (en) * 2005-08-03 2007-02-15 Cytogenix, Inc. Cell-free biosynthesis of nucleic acid
GB0614825D0 (en) * 2006-07-26 2006-09-06 Medical Res Council Method for amplification of ligation reactions
US8003330B2 (en) 2007-09-28 2011-08-23 Pacific Biosciences Of California, Inc. Error-free amplification of DNA for clonal sequencing
FR2924440B1 (fr) * 2007-12-04 2015-01-09 Pf Medicament Nouveau procede de generation et de criblage d'une banque d'anticorps
US9125845B2 (en) 2008-07-09 2015-09-08 General Electric Company DNA vaccines, uses for unprocessed rolling circle amplification product and methods for making the same
US20100008939A1 (en) * 2008-07-09 2010-01-14 General Electric Company Unprocessed rolling circle amplification product
US8921072B2 (en) * 2008-09-02 2014-12-30 General Electric Compnay Methods to generate DNA mini-circles
GB0901593D0 (en) * 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
JP2013126953A (ja) * 2010-03-31 2013-06-27 Terumo Corp リポソーム製剤の製造方法
GB201013153D0 (en) * 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
US10077459B2 (en) * 2016-05-04 2018-09-18 General Electric Company Cell-free protein expression using rolling circle amplification product
US11001868B2 (en) * 2017-08-11 2021-05-11 Global Life Sciences Solutions Operations UK Ltd Cell-free protein expression using double-stranded concatameric DNA
US10350307B2 (en) 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
AU2020351204A1 (en) 2019-09-18 2022-04-21 Intergalactic Therapeutics, Inc. Synthetic DNA vectors and methods of use
EP4083227A1 (en) * 2021-04-29 2022-11-02 4basebio, S.L.U. Linear dna with enhanced resistance against exonucleases
EP4310182A1 (en) * 2022-07-19 2024-01-24 4basebio UK Ltd Protected dna and methods for the production thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750338A (en) * 1986-10-23 1998-05-12 Amoco Corporation Target and background capture methods with amplification for affinity assays
US4994372A (en) * 1987-01-14 1991-02-19 President And Fellows Of Harvard College DNA sequencing
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5001050A (en) * 1989-03-24 1991-03-19 Consejo Superior Investigaciones Cientificas PHφ29 DNA polymerase
US5198543A (en) * 1989-03-24 1993-03-30 Consejo Superior Investigaciones Cientificas PHI29 DNA polymerase
US5043272A (en) * 1989-04-27 1991-08-27 Life Technologies, Incorporated Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers
US5455166A (en) * 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
DK51092D0 (da) * 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US6261808B1 (en) * 1992-08-04 2001-07-17 Replicon, Inc. Amplification of nucleic acid molecules via circular replicons
US5834202A (en) * 1992-08-04 1998-11-10 Replicon, Inc. Methods for the isothermal amplification of nucleic acid molecules
US6410277B1 (en) * 1993-02-19 2002-06-25 Takara Shuzo Co., Ltd. DNA polymersases with enhanced length of primer extension
US5432065A (en) * 1993-03-30 1995-07-11 United States Biochemical Corporation Cycle sequencing with non-thermostable DNA polymerases
US5714320A (en) * 1993-04-15 1998-02-03 University Of Rochester Rolling circle synthesis of oligonucleotides and amplification of select randomized circular oligonucleotides
US6096880A (en) * 1993-04-15 2000-08-01 University Of Rochester Circular DNA vectors for synthesis of RNA and DNA
CA2135579A1 (en) * 1993-11-12 1995-05-13 Gerald James Mcnabb Solid fertilizer with a modifier bound to its surfaces
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
AU2359195A (en) * 1994-04-19 1995-11-10 Thomas Jefferson University Viral ribonucleocapsid as an immunological enhancer
US6054299A (en) * 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US5614365A (en) * 1994-10-17 1997-03-25 President & Fellow Of Harvard College DNA polymerase having modified nucleotide binding site for DNA sequencing
US5602011A (en) * 1995-01-18 1997-02-11 Pharmacia Biotech Inc. Purified Thermococcus barossii DNA polymerase
WO1996038568A1 (en) * 1995-05-31 1996-12-05 Amersham Life Science, Inc. Thermostable dna polymerases
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
DK0862656T3 (da) * 1995-11-21 2001-04-09 Univ Yale Unimolekylær segmentamplifikation og -detektering
ATE324464T1 (de) * 1995-12-05 2006-05-15 Jorn Erland Koch Eine in kaskaden verlaufende vervielfältigungsreaktion von nukleinsäuren
CA2240334C (en) * 1995-12-15 2008-07-22 Amersham Life Science, Inc. Thermostable dna polymerase from thermoanaerobacter thermohydrosulfuricus and mutant enzymes thereof with exonuclease activity removed
US5827716A (en) * 1996-07-30 1998-10-27 Amersham Life Science, Inc. Modified Pol-II type DNA polymerases
US6011148A (en) * 1996-08-01 2000-01-04 Megabios Corporation Methods for purifying nucleic acids
US6042832A (en) * 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
US6200959B1 (en) * 1996-12-04 2001-03-13 Powerject Vaccines Inc. Genetic induction of anti-viral immune response and genetic vaccine for filovirus
US5882904A (en) * 1997-08-04 1999-03-16 Amersham Pharmacia Biotech Inc. Thermococcus barossii DNA polymerase mutants
US6124120A (en) * 1997-10-08 2000-09-26 Yale University Multiple displacement amplification
US6709844B1 (en) * 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US6787305B1 (en) * 1998-03-13 2004-09-07 Invitrogen Corporation Compositions and methods for enhanced synthesis of nucleic acid molecules
JP4493844B2 (ja) * 1998-03-25 2010-06-30 ランデグレン、ウルフ 錠型（ｐａｄｌｏｃｋ）プローブのローリングサークル複製
DE69936919T2 (de) * 1998-06-17 2008-05-15 Ge Healthcare Bio-Sciences Corp. Fy7 polymerase
US6316229B1 (en) * 1998-07-20 2001-11-13 Yale University Single molecule analysis target-mediated ligation of bipartite primers
CA2342837A1 (en) * 1998-09-15 2000-03-23 Yale University Artificial long terminal repeat vectors
US6235502B1 (en) * 1998-09-18 2001-05-22 Molecular Staging Inc. Methods for selectively isolating DNA using rolling circle amplification
EP1873260B1 (en) * 1998-11-09 2009-03-18 Eiken Kagaku Kabushiki Kaisha Process for synthesizing nucleic acid
US6830884B1 (en) * 1998-12-15 2004-12-14 Molecular Staging Inc. Method of amplification
JP2000225335A (ja) * 1999-02-04 2000-08-15 Shimadzu Corp 自動合成装置
US6300069B1 (en) * 1999-05-03 2001-10-09 Qiagen Gmbh Generation and amplification of nucleic acids from ribonucleic acids
US6875619B2 (en) * 1999-11-12 2005-04-05 Motorola, Inc. Microfluidic devices comprising biochannels
AU1491401A (en) * 1999-11-23 2001-06-04 Amersham Pharmacia Biotech Inc. Improving dideoxynucleotide-triphosphate utilization by the hyper-thermophilic dna polymerase from the archaeon pyrococcus furiosus
US6221603B1 (en) * 2000-02-04 2001-04-24 Molecular Dynamics, Inc. Rolling circle amplification assay for nucleic acid analysis
WO2001066138A2 (en) * 2000-03-07 2001-09-13 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
US6291187B1 (en) * 2000-05-12 2001-09-18 Molecular Staging, Inc. Poly-primed amplification of nucleic acid sequences
US6323009B1 (en) * 2000-06-28 2001-11-27 Molecular Staging, Inc. Multiply-primed amplification of nucleic acid sequences
WO2002066611A2 (en) * 2001-02-16 2002-08-29 The Board Of Trustees Of The Leland Stanford Junior University Minimal plasmid vectors that provide for persistent and high level gene expression and methods for using the same
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
US6617137B2 (en) * 2001-10-15 2003-09-09 Molecular Staging Inc. Method of amplifying whole genomes without subjecting the genome to denaturing conditions
US7309575B2 (en) * 2002-01-16 2007-12-18 The University Of North Carolina At Chapel Hill Protein purification and detection methods
US20030180781A1 (en) * 2002-03-25 2003-09-25 The Regents Of The University Of California Constructing very long DNA sequences from synthetic DNA molecules
US6815167B2 (en) * 2002-04-25 2004-11-09 Geneohm Sciences Amplification of DNA to produce single-stranded product of defined sequence and length
IL166612A0 (en) * 2002-08-29 2006-01-15 Univ Leland Stanford Junior Circular nucleic acid vectors and methods for making and using the same
EP2159285B1 (en) * 2003-01-29 2012-09-26 454 Life Sciences Corporation Methods of amplifying and sequencing nucleic acids
JP2006042601A (ja) * 2003-04-25 2006-02-16 Yaeta Endo ハイスループット合成システム
JP2006525023A (ja) * 2003-04-29 2006-11-09 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション 核酸配列の多重開始増幅
US20040223885A1 (en) * 2003-05-06 2004-11-11 Keen Randy E. Apparatus for the automated synthesis of polynucleotides
GB0315160D0 (en) * 2003-06-28 2003-08-06 Royal Holloway University Of L In vitro amplification of DNA

Also Published As

Publication number Publication date
AU2005314431B2 (en) 2011-02-17
CA2590933A1 (en) 2006-06-15
WO2006063355A3 (en) 2006-10-19
JP2008522628A (ja) 2008-07-03
EP1819828A2 (en) 2007-08-22
IL183778A0 (en) 2007-09-20
WO2006063355A2 (en) 2006-06-15
KR20070093992A (ko) 2007-09-19
US20080305142A1 (en) 2008-12-11
AU2005314431A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
BRPI0515777A (pt) biossìntese isenta de células de ácido nucléico de alta qualidade e usos dos mesmos
TWI249577B (en) Method for amplifying nucleic acid sequence
Pinker et al. PPR proteins shed a new light on RNase P biology
Matern et al. Uptake and metabolism of antibiotics roseoflavin and 8-demethyl-8-aminoriboflavin in riboflavin-auxotrophic Listeria monocytogenes
WO2016198948A1 (en) Enzymatic systems and methods for synthesizing nicotinamide mononucleotide and nicotinic acid mononucleotide
ES2716619T3 (es) Promotores de levadura para la expresión de proteínas
Rubio et al. C to U editing stimulates A to I editing in the anticodon loop of a cytoplasmic threonyl tRNA in Trypanosoma brucei
JP2023540797A (ja) 塩基編集酵素
Fath et al. Dephosphorylation of RNA polymerase I by Fcp1p is required for efficient rRNA synthesis
JPH11507830A (ja) ヒト誘導性酸化窒素シンターゼの発現
Ossa et al. The Myxococcus xanthus Nla4 protein is important for expression of stringent response-associated genes, ppGpp accumulation, and fruiting body development
JP2007259787A (ja) 遺伝子発現制御ポリヌクレオチド
JPWO2018174097A1 (ja) 細胞内在性のｄｎａ修飾酵素を利用して標的化したｄｎａの核酸塩基を特異的に変換する、細胞の核酸配列の変換方法、及びそれに用いる分子複合体
US20100203587A1 (en) Use of dna gyrase inhibitors for in vitro polypeptide synthesis reactions
Lee et al. The lysis of gram-negative Alcaligenes eutrophus and Alcaligenes latus by palmitoyl carnitine
DE60315790T2 (de) Immobilisierte Biokatalysatoren für die Herstellung von natürlichen Nukleosiden und modifizierten Analogen durch enzymatische Transglykosylierungsreaktionen
Miao et al. Effect of peptidoglycan amidase MSMEG_6281 on fatty acid metabolism in Mycobacterium smegmatis
JP2004113166A (ja) ハロペルオキシダ−ゼ活性の安定化方法
Lee et al. The regulator RamA influences cmytA transcription and cell morphology of Corynebacterium ammoniagenes
Schröder et al. Binding of the IclR-type regulator HutR in the histidine utilization (hut) gene cluster of the human pathogen Corynebacterium resistens DSM 45100
JPH06225783A (ja) 無細胞タンパク合成系を用いたタンパクの製造方法
JP5432635B2 (ja) ビタミンｋ２の製造方法
Horiuchi et al. Analysis of dofA, a fruA-dependent developmental gene, and its homologue, dofB, in Myxococcus xanthus
US20230348877A1 (en) Base editing enzymes
CN108778236A (zh) 食品、饮料、化妆品和药物制剂中的寡核苷酸

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.